Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...
Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...
From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...
Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...
Ameritas Advisory Services LLC increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 9.4% in ...
In an amicus brief, several advocacy groups warned that letting the lawsuit proceed past a motion to dismiss could open the ...
Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...
Hosted on MSN18d
Bristol Myers Says New Schizophrenia Drug Off to Strong Start(Bloomberg) -- Bristol Myers Squibb Co. said its new schizophrenia ... was a key piece of Bristol’s acquisition of Karuna. US regulators approved Cobenfy in September, becoming the first new ...
4d
Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...
The drug comes from Bristol Myers Squibb's whopping $14 billion acquisition of biotech company Karuna Therapeutics at the end of 2023. But the drug's roots are in treating Alzheimer's.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback